Log in

NASDAQ:NCNANuCana Stock Price, Forecast & News

+0.17 (+3.31 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $5.31
50-Day Range
MA: $5.87
52-Week Range
Now: $5.31
Volume23,600 shs
Average Volume39,848 shs
Market Capitalization$172.47 million
P/E RatioN/A
Dividend YieldN/A
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More
NuCana logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NCNA



Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share


Net Income$-27,340,000.00


Market Cap$172.47 million
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

NuCana (NASDAQ:NCNA) Frequently Asked Questions

How has NuCana's stock been impacted by COVID-19 (Coronavirus)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NCNA shares have decreased by 16.2% and is now trading at $5.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NuCana?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NuCana.

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for NuCana.

How were NuCana's earnings last quarter?

NuCana PLC (NASDAQ:NCNA) announced its earnings results on Tuesday, May, 19th. The company reported ($12.00) EPS for the quarter, topping the Zacks' consensus estimate of ($18.20) by $6.20. View NuCana's earnings history.

What price target have analysts set for NCNA?

5 brokerages have issued 1 year target prices for NuCana's shares. Their forecasts range from $15.00 to $25.00. On average, they expect NuCana's share price to reach $18.67 in the next year. This suggests a possible upside of 251.5% from the stock's current price. View analysts' price targets for NuCana.

What are Wall Street analysts saying about NuCana stock?

Here are some recent quotes from research analysts about NuCana stock:
  • 1. According to Zacks Investment Research, "NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. " (3/17/2020)
  • 2. HC Wainwright analysts commented, "We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate." (8/19/2019)

Has NuCana been receiving favorable news coverage?

News headlines about NCNA stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NuCana earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about NuCana.

Are investors shorting NuCana?

NuCana saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 2,470,000 shares, a drop of 5.4% from the May 31st total of 2,610,000 shares. Based on an average daily trading volume, of 93,800 shares, the days-to-cover ratio is presently 26.3 days. Currently, 8.3% of the shares of the company are short sold. View NuCana's Current Options Chain.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 74)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 52)
  • Mr. Donald Munoz, Chief Financial Officer (Age 51)

When did NuCana IPO?

(NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $5.31.

How big of a company is NuCana?

NuCana has a market capitalization of $172.47 million. The company earns $-27,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. NuCana employs 29 workers across the globe.

What is NuCana's official website?

The official website for NuCana is www.nucana.com.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.